Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 4/2014

01-04-2014 | Research Article

MicroRNA218 inhibits glioma migration and invasion via inhibiting glioma-associated oncogene homolog 1 expression at N terminus

Authors: Biao Peng, Dan Li, Mingjun Qin, Dongdong Luo, Xun Zhang, Hailin Zhao, Su Hu

Published in: Tumor Biology | Issue 4/2014

Login to get access

Abstract

Glioma is characterized by high invasion, migration and proliferation abilities. However, the molecular mechanism that triggers the development and recurrence of this tumor is also elusive. This study aims to investigate the biological function and molecular mechanism of microRNA218 in glioma. Human glioma samples were obtained and employed to investigate the correlation between microRNA218 and glioma pathological grading. Glioma cell viability was detected by the cell-counting kit-8 (CCK-8) cell counting assay. Transwell assay and wound-healing assay were employed to examine the migration and invasion of the glioma cells. The mRNA transcription and protein expression of glioma-associated oncogene homolog 1 (GLI1) were analyzed by quantitative RT-PCR and Western blot analysis, respectively. Southwestern blot assay was utilized to explore the possible interaction site of GLI1 and microRNA218. The results indicated that microRNA218 is significantly down-regulated in glioma samples and negatively correlated with the pathological grading. The cell viability was significantly decreased, and migration and invasion were significantly inhibited in microRNA218 treated cells, compared with un-treated cells. GLI1 was discovered acting as a functional downstream target of microRNA218, by which microRNA218 inhibited glioma cell migration and invasion. Southwestern blot result showed that microRNA218 targeted directly the N terminus of GLI1 molecular, and repressed the GLI1 expression in U87MG cells. In conclusion, microRNA218 could reduce the invasion and migration, and inhibit proliferation of glioma cells by suppressing the expression of GLI1 protein at the interacting with the N terminus.
Literature
1.
2.
Tu YY, Gao XC, Li G. MicroRNA-218 inhibits glioma invasion, migration, proliferation and cancer stem-like cell self-renewal by targeting the polycomb group gene Bmi1. Cancer Res. 2013. doi:10.​1158/​0008-5472.​CAN-13-0358.
3.
Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64(6):479–89.PubMed
4.
Louis DN, Ohgaki H, Wiestler QD, Gavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO classification of tumors of the central nervous system. Acta Neuropathol. 2007;114(2):97–109.PubMedCentralPubMedCrossRef
5.
Koga Y, Yasunaga M, Moriya Y, Akasu T, Fujita S, Yamamoto S, et al. Exosome can prevent RNase from degrading microRNA in fece. J Gastrointest Oncol. 2011;2(4):215–22.PubMedCentralPubMed
6.
Li YY, Wang Y, Yu L, Sun CY, Cheng DG, Yu SZ, et al. miR-146b-5p inhibits glioma migration and invasion by targeting MMP16. Cancer Lett. 2013;339(2):260–9.PubMedCrossRef
7.
Lu S, Mukkada VA, Mangray S, Cleveland K, Shillingford N, Schorl C, et al. MicroRNA profiling in mucosal biopsies of eosinophilic esophagitis patients pre and post-treatment with steroids with relationship with mRNA targets. PLoS One. 2012;7(7):e40676.PubMedCentralPubMedCrossRef
8.
9.
Li QJ, Zhou L, Yang F, Wang GX, Zheng H, Wang DS, et al. MicroRNA-10b promotes migration and invasion through CADM1 in human hepatocellular carcinoma cells. Tumor Biol. 2012;33(5):1455–65.CrossRef
10.
Sana J, Hajduch M, Michalek J, Vyzula R, Slaby O. MicroRNA and glioblastoma: roles in core signaling pathways and potential clinical implications. J Cell Mol Med. 2011;15(8):1636–44.PubMedCrossRef
11.
Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, Lopez BS, et al. Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med. 2011;3(5):279–90.PubMedCentralPubMedCrossRef
12.
13.
Skalsky RL, Cullen BR. Reduced expression of brain-enriched microRNA in glioblastomas permits targeted regulation of a cell death gene. PLoS One. 2011;6(9):e24248.PubMedCentralPubMedCrossRef
14.
Song L, Huang Q, Chen K, Liu L, Lin C, Dai T, et al. miR-218 inhibits the invasive ability of glioma cells by direct downregulation of IKK-beta. Biochem Biophys Res Commun. 2010;402(1):135–40.PubMedCrossRef
15.
Li CH, To KF, Tong JHM, Xiao ZG, Xia T, Lai PBS, et al. Enhancer of zeste homolog 2 silences microRNA-218 in human pancreatic ductal adenocarcinoma cells by inducing formation of heterochromatin. Gastroenterology. 2013;144(5):1086–97.PubMedCrossRef
16.
Yamasaki T, Seki N, Yoshino H, Itesako T, Hidaka H, Yamada Y, et al. MicroRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting Caveolin-2 involved in focal adhesion pathway. J Urol. 2013;190(3):1059–68.PubMedCrossRef
17.
18.
Lees CW, Zacharias WJ, Tremelling M, Noble CL, Nimmo ER, Tenesa A, et al. Analysis of germline GLI1 variation implicates hedgehog signaling in the regulation of intestinal inflammatory pathways. PLoS Med. 2008;5(12):e239.PubMedCentralPubMedCrossRef
19.
20.
Zhang Y, Dutta A, Abounader R. The role of microRNAs in glioma initiation and progression. Front Biosci (Landmark Ed). 2012;17(1):700–12.CrossRef
21.
Malzkorn B, Wolter M, Liesenberg F, Grzendowski M, Stuhler K, Meyer HE, et al. Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol. 2010;20(3):539–50.PubMedCrossRef
22.
Gaur A, Jewell DA, Liang Y, Ridzon D, Moore JH, Chen C, et al. Characterization of microRNA expression levels and their biological correlates in human cancer cell lines. Cancer Res. 2007;67(6):2456–68.PubMedCrossRef
23.
Setty M, Helmy K, Khan AA, Silber J, Arvey A, Neezen F, et al. Inferring transcription and microRNA-mediated regulatory programs in gliomastoma. Mol Syst Biol. 2012;8(1):605.PubMedCentralPubMed
24.
Kasper M, Regl G, Frischauf AM, Aberger F. GLI transcription factors: mediators of oncogenic Hedgehog signaling. Eur J Cancer. 2006;42(4):437–45.PubMedCrossRef
25.
Nisson M, Unden AB, Krause D, Malmqwist U, Raza K, Zaphiropoulos PG, et al. Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc Natl Acad Sci U S A. 2000;97(7):3438–43.CrossRef
26.
Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruizi AA. HEDGEHOG-GLI1 signaling regulates human growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol. 2007;17(2):165–72.PubMedCentralPubMedCrossRef
27.
Ruizi Altaba A, Mas C, Stecca B. The GLI code: an information nexus regulating cell fate, stemness and cancer. Trends Cell Biol. 2007;17(9):438–47.CrossRef
28.
Agarwal NK, Qu C, Kunkalla K, Liu Y, Vega F. Transcriptional regulation of serine/threonine protein kinase (AKT) genes by glioma-associated oncogene homolog 1. J Biol Chem. 2013;288(21):15390–401.PubMedCrossRef
29.
Shimakawa T, Tostar U, Lauth M, Palaniswamy R, Kasper M, Toftgard R, et al. Novel human Glioma-associated oncogene 1 (GLI1) splice variants reveal distinct mechanism in the terminal teransduction of the hedgehog signal. J Biol Chem. 2008;283(21):14345–54.CrossRef
30.
Metadata
Title
MicroRNA218 inhibits glioma migration and invasion via inhibiting glioma-associated oncogene homolog 1 expression at N terminus
Authors
Biao Peng
Dan Li
Mingjun Qin
Dongdong Luo
Xun Zhang
Hailin Zhao
Su Hu
Publication date
01-04-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 4/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1507-3

Other articles of this Issue 4/2014

Tumor Biology 4/2014 Go to the issue

Research Article

The association between RASSF1A promoter methylation and prostate cancer: evidence from 19 published studies

Research Article

Genetic variations at microRNA and processing genes and risk of oral cancer

Review

Collagen as a double-edged sword in tumor progression

Research Article

The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line

Research Article

Hexokinase 2 overexpression promotes the proliferation and survival of laryngeal squamous cell carcinoma

Research Article

CCNG2 expression is downregulated in colorectal carcinoma and its clinical significance
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits